U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H25N3O7S
Molecular Weight 475.5167
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERTAPENEM

SMILES

C[C@]1([H])[C@]2([H])[C@@]([H])([C@@]([H])(C)O)C(=O)N2C(=C1S[C@@]3([H])C[C@@]([H])(C(=Nc4cccc(c4)C(=O)O)O)NC3)C(=O)O

InChI

InChIKey=JUZNIMUFDBIJCM-ANEDZVCMSA-N
InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/ppa/ertapenem.html | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22 | http://www.rxlist.com/invanz-drug.htm

Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem has been designed to be effective against Gram-negative and Gram-positive bacteria. The most common drug-related adverse experiences in patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), vaginitis in females (2.1%), phlebitis/thrombophlebitis (1.3%), and vomiting (1.1%). The coadministration with probenecid to extend the half-life of ertapenem is not recommended.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P0AD65
Gene ID: 945240.0
Gene Symbol: mrdA
Target Organism: Escherichia coli (strain K12)
Target ID: P0AD68
Gene ID: 944799.0
Gene Symbol: ftsI
Target Organism: Escherichia coli (strain K12)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
75.7 μg/mL
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
70.6 μg/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
155 μg/mL
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
663.1 ug/mL
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
506.4 μg × h/mL
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
541.8 μg × h/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6225 ug*h/mL
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.8 h
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4 h
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19.3 h
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 g 1 times / day steady, intravenous
Highest studied dose
Dose: 3 g, 1 times / day
Route: intravenous
Route: steady
Dose: 3 g, 1 times / day
Sources:
healthy, 18-49 years
Health Status: healthy
Age Group: 18-49 years
Sex: M+F
Sources:
500 mg 1 times / day steady, intravenous (starting)
Dose: 500 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
vancomycin(1250 mg intravenous loading dose followed by 500 mg intravenously once the following day)
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Encephalopathy...
AEs leading to
discontinuation/dose reduction:
Encephalopathy (1 patient)
Sources:
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hallucinations, Delirium...
AEs leading to
discontinuation/dose reduction:
Hallucinations (1 patient)
Delirium (1 patient)
Sources:
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Disc. AE: Rash, Confusion...
AEs leading to
discontinuation/dose reduction:
Rash (1 patient)
Confusion (1 patient)
Seizure (1 patient)
Thrombocytopenia (1 patient)
Sources: Page: p. 184
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Other AEs: Diarrhea, Dizziness...
Other AEs:
Diarrhea (1 patient)
Dizziness (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Encephalopathy 1 patient
Disc. AE
500 mg 1 times / day steady, intravenous (starting)
Dose: 500 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
vancomycin(1250 mg intravenous loading dose followed by 500 mg intravenously once the following day)
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: M
Population Size: 1
Sources:
Delirium 1 patient
Disc. AE
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Hallucinations 1 patient
Disc. AE
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Confusion 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Rash 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Seizure 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Thrombocytopenia 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Diarrhea 1 patient
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Dizziness 1 patient
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >500 uM]
no [IC50 >500 uM]
no [IC50 >500 uM]
no
no
no
yes [IC50 56.2 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
[Efficacy of invanz proven in the treatment of intra-abdominal infections in one of the largest studies yet conducted on surgical patients].
2003
[Problems of pharmacotherapy of infections in the aged].
2003 Aug
Ertapenem therapy for community-acquired pneumonia in the elderly.
2003 Nov
Newer treatment options for skin and soft tissue infections.
2004
Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia.
2004
Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man.
2004 Apr
Gateways to clinical trials.
2004 Apr
New therapies for pneumococcal meningitis.
2004 Apr
Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
2004 Aug
Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam.
2004 Feb
Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections.
2004 Jan
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
2004 Jul
Activity of ertapenem against Neisseria gonorrhoeae.
2004 Jul
Gateways to clinical trials.
2004 Jun
Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem. Introduction.
2004 Jun
Emerging issues in infective endocarditis.
2004 Jun
Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy.
2004 Jun
Safety and tolerability of ertapenem.
2004 Jun
Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
2004 Jun
Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
2004 Jun
Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.
2004 Jun
Complicated infections of skin and skin structures: when the infection is more than skin deep.
2004 Jun
Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
2004 Jun
Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.
2004 Jun
In vitro activity of ertapenem: review of recent studies.
2004 Jun
Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
2004 Jun
Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.
2004 Jun
In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.
2004 Jun
Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam.
2004 Mar
Gateways to clinical trials.
2004 Mar
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
2004 May 1
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
2004 Nov
In vitro activity of ertapenem against selected respiratory pathogens.
2004 Nov
[Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients].
2004 Oct
Gateways to clinical trials.
2004 Oct
Appropriate use of the carbapenems.
2004 Oct
Ertapanem therapy for community-acquired pneumonia in the elderly.
2004 Oct
Beta-lactam antibiotics: newer formulations and newer agents.
2004 Sep
In vitro activity of antimicrobial agents against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
2005 Apr
Ertapenem: review of a new carbapenem.
2005 Feb
[Activity of ertapenem and 19 other antimicrobial agents against beta-lactam-resistant Streptococcus pneumoniae and Haemophilus influenzae respiratory tract isolates].
2005 Feb
Ertapenem-associated seizures in a peritoneal dialysis patient.
2005 Feb
Distribution and characteristics of Escherichia coli clonal group A.
2005 Jan
Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery.
2005 Jun
Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.
2005 Jun
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems.
2005 Mar
In vitro activity of ertapenem against bacteraemic pneumococci: report of a French multicentre study including 339 strains.
2005 Mar
Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
2005 May
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
2005 May
Characterization of a new integron containing bla(VIM-1) and aac(6')-IIc in an Enterobacter cloacae clinical isolate from Greece.
2005 May
Patents

Sample Use Guides

1 g given once a day. Intravenous infusion for up to 14 days or intramuscular injection for up to 7 days.
Route of Administration: Other
The MICs of ertapenem are MIC(50) = 0.032 μg/ml; MIC(90) = 0.064 μg/ml in vitro activity of ertapenem against N.gonorrhoeae isolates.
Name Type Language
ERTAPENEM
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
(4R,5S,6S)-3-(((3S,5S)-5-((M-CARBOXYPHENYL)CARBAMOYL)-3-PYRROLIDINYL)THIO)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 3-((5-(((3-CARBOXYPHENYL)AMINO)CARBONYL)-3-PYRROLIDINYL)THIO)-6-(1-HYDROXYETHYL)-4-METHYL-7-OXO-, (4R-(3(3S*,5S*), 4.ALPHA.,5.BETA.,6.BETA.(R*)))-
Systematic Name English
ERTAPENEM [MI]
Common Name English
ERTAPENEM [INN]
Common Name English
ERTAPENEM [VANDF]
Common Name English
ERTAPENEM [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000175496
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
WHO-ATC J01DH03
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NCI_THESAURUS C260
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
WHO-VATC QJ01DH03
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
LIVERTOX 366
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
Code System Code Type Description
FDA UNII
G32F6EID2H
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
LACTMED
Ertapenem
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
MESH
C446479
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
RXCUI
325642
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY RxNorm
EVMPD
SUB25388
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
DRUG CENTRAL
1046
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
MERCK INDEX
M5001
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB00303
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
HSDB
8020
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
CAS
153832-46-3
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
PUBCHEM
150610
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
NCI_THESAURUS
C61752
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
INN
8049
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
EPA CompTox
153832-46-3
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
ChEMBL
CHEMBL1359
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
WIKIPEDIA
ERTAPENEM
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY